Candel Therapeutics (CADL) investor relations material

Key clinical programs and mechanisms

• Lead asset aglatimagene is a first-in-class, off-the-shelf prodrug for pan-solid tumors, inducing individualized anti-tumor immune responses.

• Proof of concept and positive phase III data in prostate cancer; additional data in lung and pancreatic cancers.

• Linoserpaturev, a next-generation oncolytic herpes simplex virus, showed doubling of median overall survival in recurrent glioblastoma and achieved Fast Track and Orphan Drug designations.

• Both assets leverage viral immunotherapy to stimulate local and systemic anti-tumor immunity.

• Over 1,000 patients dosed with aglatimagene, supporting safety and tolerability profile.

Financial and corporate highlights

• Strong executive and research advisory teams with industry leaders.

• Financial runway extends into Q1 2028, with potential for commercialization under current funding.

• Consistent track record of meeting milestones and mitigating risks.

Clinical trial results and upcoming milestones

• Phase III trial in metastatic progressive non-small cell lung cancer to initiate soon; new prostate cancer biomarker data expected in Q3; BLA filing for aglatimagene in prostate cancer planned for Q4.

• Prostate cancer trial focused on patients choosing radiotherapy, aiming to increase cure rates and reduce recurrence and need for salvage therapies.

• No direct competition in this clinical space; trial design included 745 patients, randomized 2:1, with disease-free survival as the primary endpoint.

• Statistically significant improvements in disease-free survival and pathological complete response (80% vs. 63% for placebo) at two years.

• Durable improvements in prostate cancer-specific DFS and time to metastasis, especially in intermediate-risk patients (90% improvement in time to metastasis).